A New Type of Ser Substitution for γ Arg-275 in Fibrinogen Kamogawa I Characterized by Impaired Fibrin Assembly

Summary

A new type of substitution, Arg to Ser at γ275, has been found in a heterozygous dysfibrinogen derived from a 23-year-old woman with no major bleeding or thrombosis. By sequence analyses of the affected γ-chain and its gene, we found a single amino acid substitution of γ Arg-275 to Ser in an aberrant γ (274-302) residue peptide isolated from lysyl endopeptidase-digests of the patient’s fibrinogen. In agreement with this amino acid substitution, we identified a single nucleotide exchange of A for C at position 5728 in the γ-chain gene creating a codon (AGC) encoding Ser instead of the codon (CGC) encoding Arg at position γ 275. Like two other known types of mutants with a His or Cys substitution at this position, the functional abnormality was characterized by delayed fibrin polymerization, most likely due to impaired abutting of two D domains of adjacent fibrin monomers in the same strand of fibrin protofibrils. The structural derangement that affects the D:D association may not be so severe as compared with those of Cys and His mutants, possessing an additional disulfide-linked Cys molecule and an imidazole ring at the mutation site, respectively.

• References

• 1 Mosesson MW, Siebenlist KR, DiOrio JP, Matsuda M, Hainfeld JF, Wall JS. The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and fibrinogen Tokyo II (γ 275 Arg → Cys). J Clin Invest 1995; 96: 1053-8.
• 2 Reber P, Furlan M, Henschen A, Kaudewitz H, Barbui T, Hilgard P, Nenci GG, Berrettini M, Beck EA. Three abnormal fibrinogen variants with the same amino acid substitution (γ 275-Arg → His): Fibrinogens Bergamo II, Essen and Perugia. Thromb Haemost 1986; 56: 401-6.
• 3 Yamazumi K, Terukina S, Onohara S, Matsuda M. Normal plasmic cleavage of the γ-chain variant of “fibrinogen Saga” with an Arg-275 to His substitution. Thromb Haemost 1988; 60: 476-80.
• 4 Yoshida N, Imaoka S, Hirata H, Matsuda M, Asakura S.. Heterozygous abnormal fibrinogen Osaka III with the replacement of γ arginine-275 by histidine has an apparently higher molecular weight γ-chain variant. Thromb Haemost 1992; 68: 534-8.
• 5 Matsuda M. The structure-function relationship of hereditary dysfibrinogens. Int J Hematol 1996; 64: 167-79.
• 6 Ebert RF. (ed) 1994. Index of variant human fibrinogens. CRC Press, Boca Raton; Florida:
• 7 Côté HCF, Lord ST, Pratt KP. γ chain dysfibrinogenemias: Molecular structure-function relationships of naturally occurring mutations in the γ chain of human fibrinogen. Blood 1998; 92: 2195-212.
• 8 Terukina S, Matsuda M, Hirata H, Takeda Y, Miyata T, Takao T, Shimonishi Y. Substitution of γ Arg-275 by Cys in an abnormal fibrinogen, “Fibrinogen Osaka II”. Evidence for a unique solitary cystine structure at the mutation site. J Biol Chem 1988; 263: 13579-87.
• 9 Yoshida N, Ota K, Moroi M, Matsuda M. An apparently higher molecular-weight γ-chain variant in a new congenital abnormal fibrinogen Tochigi characterized by the replacement of γ arginine-275 by cysteine. Blood 1988; 71: 480-7.
• 10 Mimuro J, Muramatsu S, Maekawa H, Sakata Y, Kaneko M, Yoshitake S, Okuma M, Ito Y, Takeda Y, Matsuda M. Gene analyses of abnormal fibrinogens with a mutation in the γ chain. Int J Hematol 1992; 56: 129-34.
• 11 Olexa SA, Budzynski AZ. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci USA 1980; 77: 1374-8.
• 12 Laudano AP, Doolittle RF. Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers. Proc Natl Acad Sci USA 1978; 75: 3085-9.
• 13 Laudano AP, Doolittle RF. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirement, number of binding sites and species differences. Biochemistry 1980; 19: 1013-9.
• 14 Chen RD, Doolittle RF. γ-γ Cross-linking site in human and bovine fibrin. Biochemistry 1971; 10: 4486-91.
• 15 Yee VC, Pratt KP, Côté HCF, Le Trong I, Chung DW, Davie EW, Stenkamp RE, Teller DC. Crystal structure of a 30 kDa- C-terminal fragment from the γ chain of human fibrinogen. Structure 1997; 5: 125-38.
• 16 Pratt KP, Côté HCF, Chung DW, Stenkamp RE, Davie EW. The fibrin polymerization pocket: three-dimensional structure of a 30 kDa C terminal γ-chain fragment complexed with the peptide Gly-Pro-Arg-Pro. Proc Natl Acad Sci USA 1997; 94: 7176-81.
• 17 Spraggon G, Everse SJ, Doolittle RF. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature 1997; 389: 455-62.
• 18 Everse SJ, Spraggon G, Doolittle RF. A three-dimensional consideration of variant human fibrinogens. Thromb Haemost 1998; 80: 1-9.
• 19 Matsuda M, Baba M, Morimoto K, Nakamikawa C. “Fibrinogen Tokyo II”. An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules. J Clin Invest 1983; 72: 1034-41.
• 20 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
• 21 Yamazumi K, Shimura K, Terukina S, Takahashi N, Matsuda M. A γ methionine-310 to threonine substitution and consequent N-glycosylation at γ asparagine-308 identified in a congenital dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen Asahi. J Clin Invest 1989; 83: 1590-7.
• 22 Deutsch DG, Mertz ET. Plasminogen: Purification from human plasma by affinity chromatography. Science 1970; 170: 1095-6.
• 23 Lorand D, Credo RB, Janus TJ. Factor XIII (fibrin-stabilizing factor). Methods Enzymol 1981; 80: 333-41.
• 24 Lundblad RL.. A rapid method for the purification of bovine thrombin and the inhibition of the purified enzyme with phenylmethylsulfonyl fluoride. Biochemistry 1971; 10:: 2501-6.
• 25 Marder VJ, Shulman NR, Carroll WF. High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. J Biol Chem 1969; 244: 2111-9.
• 26 Barlow GH, Summaria L, Robbins KC. Molecular weight studies on human plasminogen and plasmin at the mg level. J Biol Chem 1969; 244: 1138-41.
• 27 Shwartz ML, Pizzo SV, Hill RL, McKee PA. Human factor XIII from plasma and platelets. J Biol Chem 1973; 248: 1395-407.
• 28 Gralnick HR, Givelber HM, Shainoff JR, Finlayson JS. Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release. J Clin Invest 1971; 50: 1819-30.
• 29 Niwa K, Takebe M, Sugo T, Kawata Y, Mimuro J, Asakura S, Sakata Y, Mizushima J, Maeda A, Endo H, Matsuda M. A γ Gly-268 to Glu substitution is responsible for impaired fibrin assembly in a homozygous dysfibrinogen Kurashiki I. Blood 1996; 87: 4686-94.
• 30 Gyllensten UB, Erlich HA. Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing the HLADQA locus. Proc Natl Acad Sci USA 1988; 85: 7652-6.
• 31 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957; 17: 237-47.
• 32 Suenson E, Bjerrum P, Holm A, Lind B, Meldal M, Selmer J, Petersen LC. The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation. J Biol Chem 1990; 265: 22228-37.
• 33 Pellowes AP, Brennan SO, Ridgway HJ, Heaton DC, George PM. Electro-spray ionization mass spectrometry identification of fibrinogen Banks Peninsula (γ 280 Tyr → Cys): a new variant with defective polymerization. Br J Haematol 1998; 101: 24-31.
• 34 Okumura N, Furihata K, Terasawa F, Nakagoshi R, Ueno I, Katsuyama T. Fibrinogen Matsumoto I: A γ 364 Asp → His (GAT → CAT) substitution associated with defective fibrin polymerization. Thromb Haemost 1996; 75: 887-91.
• 35 Reber P, Furlan M, Rupp C, Kehl M, Henschen A, Mannucci P, Beck E. Characterization of fibrinogen Milano I: amino acid exchange γ 330 Asp → Val impairs fibrin polymerization. Blood 1986; 67: 1751-6.
• 36 Terukina S, Yamazumi K, Okamoto K, Yamashita H, Ito Y, Matsuda M. Fibrinogen Kyoto III: a congenital dysfibrinogen with a γ-aspartic acid-330 to tyrosine substitution manifesting impaired fibrin monomer polymerization. Blood 1989; 74: 2681-7.
• 37 Miyata T, Furukawa K, Iwanaga S, Takamatsu J, Saito H. Fibrinogen Nagoya, a replacement of glutamine-329 by arginine in the γ-chain that impairs the polymerization of fibrin monomer. J Biochem 1989; 105: 10-4.
• 38 Maekawa H, Yamazumi K, Muramatsu S, Kaneko M, Hirata H, Takahashi N, Arocha-Piñango CL, Rodriguez S, Nagy H, Perez-Requejo JL, Matsuda M. Fibrinogen Lima: a homozygous dysfibrinogen with an Aα-arginine-141 to serine substitution associated with extra N-glycosylation at Aα-as-paragine-139. J Clin Invest 1992; 90: 67-76.
• 39 Maekawa H, Yamazumi K, Muramatsu S, Kaneko M, Hirata H, Takahashi N, de Bosch NB, Carvajal Z, Ojeda A, Arocha-Piñango CL, Matsuda M. An Aa Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen, fibrinogen Caracas II, characterized by impaired fibrin gel formation. J Biol Chem 1991; 266: 11575-81.